The Exchange has sought clarification from Laurus Labs Limited for the quarter ended 30-Sep-2025 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Financial results submitted in XBRL with discrepancies The response of the Company is awaited.
LAURUSLABS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 3.7 pts less than Nifty Midcap 150 and 3.0 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
The National Stock Exchange has asked Laurus Labs to clarify discrepancies found in the XBRL format of its financial results for the quarter ended 30 September 2025. This is a procedural query under SEBI's Listing Regulations (Regulation 33), which governs how listed companies submit their quarterly financial results. The company has not yet submitted its response. XBRL discrepancies are typically minor technical or formatting issues rather than substantive errors in the underlying numbers.
This is a routine compliance clarification request and is unlikely to materially affect the stock. Investors should watch for the company's response to confirm there are no actual financial reporting issues, but no immediate red flag is indicated.